Works about EXENATIDE

Results: 562

Enhanced lymphatic transportation of SLN by mimicking oligopeptide transportation route.

Published in:

Asian Journal of Pharmaceutical Sciences, 2025, v. 20, n. 3, p. 1, doi. 10.1016/j.ajps.2025.101019

By:

Fuya Jia;
Xiaoxing Fan;
Licheng Wu;
Yating Wang;
Jisen Zhang;
Zhou Zhou;
Lian Li;
Jingyuan Wen;
Yuan Huang

Publication type:

Article

Pharmacotherapy for obesity: are we ready to select, tailor and combine pharmacotherapy to achieve more ambitious goals?

Published in:

Frontiers in Endocrinology, 2025, p. 1, doi. 10.3389/fendo.2025.1569468

By:

Steenackers, Nele;
Toumazia, Julia;
Deleus, Ellen;
Mertens, Ann;
Lannoo, Matthias;
Pazmino, Sofia;
van Laar, Amar Daniël Emanuel;
Van der Schueren, Bart;
Vangoitsenhoven, Roman

Publication type:

Article

Effects of Exenatide plus Metformin versus Metformin alone on insulin resistance in women with Polycystic Ovary Syndrome: A systematic review and meta‐analysis.

Published in:

Journal of Obstetrics & Gynaecology Research, 2025, v. 51, n. 5, p. 1, doi. 10.1111/jog.16296

By:

Al‐Qudah, Abd‐alrahman;
Al‐Hanaktah, Mohammad;
Albadaineh, Reham

Publication type:

Article

Comprehensive study of GLP‐1 effects suggests neuropsychiatric benefits.

Published in:: Brown University Psychopharmacology Update, 2025, v. 36, n. 5, p. 4, doi. 10.1002/pu.31301
Publication type:: Article

hUCMSCs carrying exenatide prevent T1DM by improving intestinal microflora composition and islet tissue damage repair.

Published in:

Molecular Medicine, 2022, v. 28, n. 1, p. 1, doi. 10.1186/s10020-022-00526-0

By:

Wang, Wei;
Wang, Yahao;
Chi, Jingwei;
Tan, Xiaojun;
Hu, Jianxia;
Ma, Xiaolong;
Sun, Xiaofang;
Che, Kui;
Lv, Wenshan;
Wang, Yangang

Publication type:

Article

Exenatide regulates Th17/Treg balance via PI3K/Akt/FoxO1 pathway in db/db mice.

Published in:

Molecular Medicine, 2022, v. 28, n. 1, p. 1, doi. 10.1186/s10020-022-00574-6

By:

Xu, Qinqin;
Zhang, Xiaoling;
Li, Tao;
Shao, Shiying

Publication type:

Article

Long-Term Efficiency of Twice-Daily Exenatide in Type 2 Diabetes Mellitus: A Real-Life Study.

Published in:

Endocrinology Research & Practice, 2024, v. 28, n. 2, p. 77, doi. 10.5152/erp.2024.23395

By:

Ünal, Mehmet Çağrı;
Terzioğlu, Gülsüm Ceren;
Kaya, Deniz Yıldız;
Arayıcı, Mehmet Emin;
Bayraktar, Fırat;
Çömlekci, Abdurrahman;
Demir, Tevfik

Publication type:

Article

New-Onset Atrial Fibrillation After Exenatide Injection: Coincidence or Consequence?

Published in:

Endocrinology Research & Practice, 2023, v. 27, n. 4, p. 241, doi. 10.5152/erp.2023.23262

By:

Yamantürk, Yakup Yunus;
Esenboğa, Kerim;
Yılmaz, Gözde Cansu;
Baskovski, Emir;
Candemir, Başar;
Şahin, Mustafa

Publication type:

Article

Hyperglycaemia in type 2 diabetes: Newer blood glucose-lowering therapies.

Published in:

Diabetes & Primary Care, 2015, v. 17, n. 6, p. 302

By:

Kenny, Colin

Publication type:

Article

Hyperglycaemia in type 2 diabetes: Newer blood glucose-lowering therapies - update.

Published in:

Diabetes & Primary Care, 2012, v. 14, n. 2, p. 102

By:

Munro, Neil

Publication type:

Article

The role of mast cells in cellular modifications evoked by Exendin-4 in treated wounds: a preclinical study.

Published in:

Journal of Wound Care, 2022, v. 31, n. 8, p. 701, doi. 10.12968/jowc.2022.31.8.701

By:

Paroli, Gaia;
Murciano, Nicoletta;
Mancini, Caterina;
Soldaini, Marta;
Rijli, Sarah;
DeSiena, Gaetano;
Bacci, Stefano

Publication type:

Article

Fasting plasma c-peptide level predicts the response of glucagon-like peptide-1 agonist (exenatide) add on to metformin monotherapy in obese type 2 diabetics.

Published in:

Journal of Experimental & Clinical Medicine / Deneysel ve Klinik Tip Dergisi, 2022, v. 39, n. 3, p. 798, doi. 10.52142/omujecm.39.3.39

By:

GÜNGÖR, Kağan;
ÖZTÜRK, Serkan;
CAN, Bülent;
SARGIN, Mehmet

Publication type:

Article

Exenatide with Metformin Ameliorated Visceral Adiposity and Insulin Resistance.

Published in:

Journal of Diabetes Research, 2018, p. 1, doi. 10.1155/2018/4019248

By:

Du, Xuan;
Lu, Wen;
Lu, Zijun;
Shao, Xinyu;
Hu, Chunhong;
Shi, Bimin

Publication type:

Article

Exenatide regulates inflammation and the production of reactive oxygen species via inhibition of S1PR2 synthesis.

Published in:

Advances in Clinical & Experimental Medicine, 2021, v. 30, n. 5, p. 555, doi. 10.17219/acem/133483

By:

Yunyun Yang;
Qingyi Zhao

Publication type:

Article

Anti‐obesity pharmacological agents for polycystic ovary syndrome: A systematic review and meta‐analysis to inform the 2023 international evidence‐based guideline.

Published in:

Obesity Reviews, 2024, v. 25, n. 5, p. 1, doi. 10.1111/obr.13704

By:

Goldberg, Alyse;
Graca, Sandro;
Liu, Jing;
Rao, Vibhuti;
Witchel, Selma Feldman;
Pena, Alexia;
Li, Rong;
Mousa, Aya;
Tay, Chau Thien;
Pattuwage, Loyal;
Teede, Helena;
Yildiz, Bulent O.;
Ee, Carolyn

Publication type:

Article

Trends in the use of drugs with weight‐loss effect: Scandinavian study from 2017 to 2023.

Published in:

Diabetes, Obesity & Metabolism, 2025, v. 27, n. 5, p. 2901, doi. 10.1111/dom.16291

By:

Ruiz, Paz Lopez‐Doriga;
Hindenes, Lars Bakke;
Karlstad, Øystein;
Nøkleby, Kjersti;
Meyer, Haakon E.;
Mailhac, Aurélie;
Ljung, Rickard;
Thomsen, Reimar W.;
Furu, Kari

Publication type:

Article

Front Cover.

Published in:

Diabetes, Obesity & Metabolism, 2025, v. 27, n. 4, p. C1, doi. 10.1111/dom.16322

By:

Lin, Chia‐Ming;
Chen, Jo‐Ching;
Meyerowitz‐Katz, Gideon;
Huang, Yu‐Nan;
Su, Pen‐Hua

Publication type:

Article

Survodutide, a glucagon receptor/glucagon‐like peptide‐1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo‐controlled, dose‐finding, phase 2 trial.

Published in:

Diabetes, Obesity & Metabolism, 2025, v. 27, n. 2, p. 993, doi. 10.1111/dom.16052

By:

le Roux, Carel W.;
Steen, Oren;
Lucas, Kathryn J.;
Ekinci, Elif I.;
Startseva, Elena;
Unseld, Anna;
Hussain, Samina Ajaz;
Hennige, Anita M.

Publication type:

Article

Cost‐utility analysis of once‐weekly insulin icodec and once‐daily insulin glargine in patients with type 2 diabetes receiving basal‐bolus insulin therapy in China.

Published in:

Diabetes, Obesity & Metabolism, 2025, v. 27, n. 1, p. 377, doi. 10.1111/dom.16031

By:

Dai, Nan;
Su, Xiaorong;
Wang, Yong

Publication type:

Article

Early uptake of semaglutide for type 2 diabetes in Scandinavia and characteristics of initiators in Denmark: A register‐based drug utilization study.

Published in:

Diabetes, Obesity & Metabolism, 2024, v. 26, n. 11, p. 5479, doi. 10.1111/dom.15876

By:

Rasmussen, Lotte;
Andersen, Jacob Harbo;
Karlstad, Øystein;
Giunta, Diego Hernan;
Linder, Marie;
Furu, Kari;
Pottegård, Anton

Publication type:

Article

Sodium‐glucose co‐transporter‐2 inhibitors: A paradigm shift in treatment for type 2 diabetes.

Published in:

Diabetes, Obesity & Metabolism, 2024, v. 26, p. 3, doi. 10.1111/dom.15963

By:

Matthews, David R.

Publication type:

Article

Medication adherence to sodium‐glucose cotransporter‐2 inhibitors versus glucagon‐like peptide‐1 receptor agonists: A meta‐analysis.

Published in:

Diabetes, Obesity & Metabolism, 2024, v. 26, n. 10, p. 4544, doi. 10.1111/dom.15809

By:

Johnson, Conner E.;
Sussman, Whitney B.;
Weeda, Erin R.

Publication type:

Article

Real‐world safety profile of once‐weekly semaglutide in people with type 2 diabetes: Analysis of pooled data from the SemaglUtide Real‐world Evidence (SURE) programme.

Published in:

Diabetes, Obesity & Metabolism, 2024, v. 26, n. 10, p. 4429, doi. 10.1111/dom.15794

By:

Yale, Jean‐François;
Major‐Pedersen, Atheline;
Catarig, Andrei‐Mircea;
Jain, Rashmi;
Menzen, Markus;
Holmes, Patrick

Publication type:

Article

Adverse event comparison between glucagon‐like peptide‐1 receptor agonists and other antiobesity medications following bariatric surgery.

Published in:

Diabetes, Obesity & Metabolism, 2024, v. 26, n. 9, p. 3906, doi. 10.1111/dom.15737

By:

Samuels, Jason M.;
Niswender, Kevin D.;
Roumie, Christianne L.;
Spann, Matthew D.;
Flynn, C. Robb;
Ye, Fei;
Blankush, Joseph;
Irlmeier, Rebecca;
Funk, Luke M.;
Patel, Mayur B.

Publication type:

Article

Time trends and regional variation in utilization of antidiabetic medicines in China, 2015–2022.

Published in:

Diabetes, Obesity & Metabolism, 2024, v. 26, n. 7, p. 2752, doi. 10.1111/dom.15594

By:

Zhang, Jieqiong;
Xu, Sen;
Liu, Xingyu;
Zhang, Jinwei;
Hu, Shuchen;
Liu, Xiaoyong;
Yang, Caijun;
Fang, Yu

Publication type:

Article

Suicidality among users of glucagon‐like peptide‐1 receptor agonists: An emerging signal?

Published in:

Diabetes, Obesity & Metabolism, 2024, v. 26, n. 4, p. 1150, doi. 10.1111/dom.15459

By:

Lau, Darren;
Gamble, John‐Michael

Publication type:

Article

Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials.

Published in:

Diabetes, Obesity & Metabolism, 2024, v. 26, n. 2, p. 473, doi. 10.1111/dom.15333

By:

Patel, Hiren;
Khunti, Kamlesh;
Rodbard, Helena W.;
Bajaj, Harpreet S.;
Bray, Ross;
Kindracki, Zbigniew;
Rodríguez, Ángel

Publication type:

Article

Diabetes, antidiabetic medications and risk of dementia: A systematic umbrella review and meta‐analysis.

Published in:

Diabetes, Obesity & Metabolism, 2024, v. 26, n. 2, p. 441, doi. 10.1111/dom.15331

By:

Kuate Defo, Alvin;
Bakula, Veselko;
Pisaturo, Alessandro;
Labos, Christopher;
Wing, Simon S.;
Daskalopoulou, Stella S.

Publication type:

Article

Sustained metabolic benefits of ΔTRTX‐Ac1, a tarantula venom‐derived peptide, when administered together with exenatide in high‐fat fed mice.

Published in:

Diabetes, Obesity & Metabolism, 2024, v. 26, n. 1, p. 329, doi. 10.1111/dom.15319

By:

Coulter‐Parkhill, Aimee;
Tanday, Neil;
Cobice, Diego;
McLaughlin, Christopher M.;
McClean, Stephen;
Gault, Victor A.;
Irwin, Nigel

Publication type:

Article

Efficacy and safety of adding once‐weekly dulaglutide to basal insulin for inadequately controlled type 2 diabetes in Chinese patients (AWARD‐CHN3): A randomized, double‐blind, placebo‐controlled, phase III trial.

Published in:

Diabetes, Obesity & Metabolism, 2023, v. 25, n. 12, p. 3690, doi. 10.1111/dom.15263

By:

Wang, Weimin;
Yan, Xin;
Cheng, Zhifeng;
Zhang, Qiqi;
Wang, Rui;
Deng, Yuying;
Ma, Jianhua;
Zhu, Dalong

Publication type:

Article

Cardiovascular efficacy and safety of antidiabetic agents: A network meta‐analysis of randomized controlled trials.

Published in:

Diabetes, Obesity & Metabolism, 2023, v. 25, n. 12, p. 3560, doi. 10.1111/dom.15251

By:

Sohn, Minji;
Frias, Juan P.;
Lim, Soo

Publication type:

Article

Glucose‐lowering drug use in migrants and native Danes with type 2 diabetes: Disparities in combination therapy and drug types.

Published in:

Diabetes, Obesity & Metabolism, 2023, v. 25, n. 11, p. 3307, doi. 10.1111/dom.15230

By:

Isaksen, Anders Aasted;
Sandbæk, Annelli;
Skriver, Mette Vinther;
Bjerg, Lasse

Publication type:

Article

Acute pharmacodynamic responses to exenatide: Drug‐induced increases in insulin secretion and glucose effectiveness.

Published in:

Diabetes, Obesity & Metabolism, 2023, v. 25, n. 9, p. 2586, doi. 10.1111/dom.15143

By:

Taylor, Simeon I.;
Montasser, May E.;
Yuen, Ashley H.;
Fan, Hubert;
Yazdi, Zhinoosossadat Shahidzadeh;
Whitlatch, Hilary B.;
Mitchell, Braxton D.;
Shuldiner, Alan R.;
Muniyappa, Ranganath;
Streeten, Elizabeth A.;
Beitelshees, Amber L.

Publication type:

Article

Efficacy and safety of once‐weekly efpeglenatide in people with suboptimally controlled type 2 diabetes: The AMPLITUDE‐D, AMPLITUDE‐L and AMPLITUDE‐S randomized controlled trials.

Published in:

Diabetes, Obesity & Metabolism, 2023, v. 25, n. 8, p. 2084, doi. 10.1111/dom.15079

By:

Aroda, Vanita R.;
Frias, Juan Pablo;
Ji, Linong;
Niemoeller, Elisabeth;
Nguyên‐Pascal, My‐Liên;
Denkel, Karl;
Espinasse, Melanie;
Guo, Hailing;
Baek, SeungJae;
Choi, JaeDuk;
Lingvay, Ildiko

Publication type:

Article

Albuminuria‐lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes: A randomized cross‐over clinical study.

Published in:

Diabetes, Obesity & Metabolism, 2023, v. 25, n. 6, p. 1758, doi. 10.1111/dom.15033

By:

van der Aart‐van der Beek, Annemarie B.;
Apperloo, Ellen;
Jongs, Niels;
Rouw, Dennis B.;
Sjöström, C. David;
Friedli, Iris;
Johansson, Lars;
van Raalte, Daniël H.;
Hoogenberg, Klaas;
Heerspink, Hiddo J. L.

Publication type:

Article

Sex differences in the complications, care and clinical outcomes of patients with type 2 diabetes in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).

Published in:

Diabetes, Obesity & Metabolism, 2023, v. 25, n. 6, p. 1473, doi. 10.1111/dom.14993

By:

Green, Jennifer B.;
Merrill, Peter;
Lokhnygina, Yuliya;
Mentz, Robert J.;
Alfredsson, Joakim;
Holman, Rury R.

Publication type:

Article

Rationale and design of the phase 3a development programme (ONWARDS 1–6 trials) investigating once‐weekly insulin icodec in diabetes.

Published in:

Diabetes, Obesity & Metabolism, 2023, v. 25, n. 2, p. 331, doi. 10.1111/dom.14871

By:

Philis‐Tsimikas, Athena;
Bajaj, Harpreet S.;
Begtrup, Kamilla;
Cailleteau, Roman;
Gowda, Amoolya;
Lingvay, Ildiko;
Mathieu, Chantal;
Russell‐Jones, David;
Rosenstock, Julio

Publication type:

Article

Comparing a daily versus weekly titration algorithm in people with type 2 diabetes switching from basal insulin to iGlarLixi in the LixiLan ONE CAN randomized trial.

Published in:

Diabetes, Obesity & Metabolism, 2022, v. 24, n. 10, p. 1998, doi. 10.1111/dom.14787

By:

Hramiak, Irene;
Gerstein, Hertzel C.;
Leiter, Lawrence A.;
Yale, Jean‐François;
Bajaj, Harpreet S.;
Stewart, John;
Toutounji, Marie‐Josée;
Harris, Stewart B.

Publication type:

Article

Effect of once‐weekly semaglutide versus thrice‐daily insulin aspart, both as add‐on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open‐label, multinational, phase 3b trial

Published in:

Diabetes, Obesity & Metabolism, 2022, v. 24, n. 9, p. 1788, doi. 10.1111/dom.14765

By:

Kellerer, Monika;
Kaltoft, Margit Staum;
Lawson, Jack;
Nielsen, Lasse Lykke;
Strojek, Krzysztof;
Tabak, Ömür;
Jacob, Stephan

Publication type:

Article

Combination therapy with exenatide decreases the dapagliflozin‐induced changes in brain responses to anticipation and consumption of palatable food in patients with type 2 diabetes: A randomized controlled trial.

Published in:

Diabetes, Obesity & Metabolism, 2022, v. 24, n. 8, p. 1588, doi. 10.1111/dom.14732

By:

van Ruiten, Charlotte C.;
Veltman, Dick J.;
Wijdeveld, Madelief;
ten Kulve, Jennifer S;
Kramer, Mark H. H.;
Nieuwdorp, Max;
IJzerman, Richard G.

Publication type:

Article

Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT).

Published in:

Diabetes, Obesity & Metabolism, 2022, v. 24, n. 5, p. 899, doi. 10.1111/dom.14650

By:

Lavynenko, Olga;
Abdul‐Ghani, Muhammad;
Alatrach, Mariam;
Puckett, Curtiss;
Adams, John;
Abdelgani, Siham;
Alkhouri, Naim;
Triplitt, Curtis;
Clarke, Geoffrey D.;
Vasquez, Juan A.;
Li, Jinqi;
Cersosimo, Eugenio;
Gastaldelli, Amalia;
DeFronzo, Ralph A.

Publication type:

Article

Cost‐effectiveness of second‐line empagliflozin versus liraglutide for type 2 diabetes in the United States.

Published in:

Diabetes, Obesity & Metabolism, 2022, v. 24, n. 4, p. 652, doi. 10.1111/dom.14625

By:

Reifsnider, Odette S.;
Pimple, Pratik;
Brand, Sarah;
Bergrath Washington, Evelien;
Shetty, Sharash;
Desai, Nihar R.

Publication type:

Article

Effects of short‐acting exenatide added three times daily to insulin therapy on bone metabolism in type 1 diabetes.

Published in:

Diabetes, Obesity & Metabolism, 2022, v. 24, n. 2, p. 221, doi. 10.1111/dom.14568

By:

Johansen, Nicklas J.;
Dejgaard, Thomas F.;
Lund, Asger;
Schlüntz, Camilla;
Hartmann, Bolette;
Holst, Jens J.;
Vilsbøll, Tina;
Andersen, Henrik U.;
Knop, Filip K.

Publication type:

Article

Comparative efficacy of glucose‐lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta‐analysis.

Published in:

Diabetes, Obesity & Metabolism, 2021, v. 23, n. 9, p. 2116, doi. 10.1111/dom.14451

By:

Tsapas, Apostolos;
Karagiannis, Thomas;
Kakotrichi, Panagiota;
Avgerinos, Ioannis;
Mantsiou, Chrysanthi;
Tousinas, Georgios;
Manolopoulos, Apostolos;
Liakos, Aris;
Malandris, Konstantinos;
Matthews, David R.;
Bekiari, Eleni

Publication type:

Article

Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial.

Published in:

Diabetes, Obesity & Metabolism, 2021, v. 23, n. 8, p. 1851, doi. 10.1111/dom.14410

By:

Ruiten, Charlotte C.;
der Aart‐van der Beek, Annemarie B;
IJzerman, Richard G.;
Nieuwdorp, Max;
Hoogenberg, Klaas;
Raalte, Daniël H;
Heerspink, Hiddo J. L.

Publication type:

Article

The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: Results of a pilot randomized, double‐blind, placebo‐controlled trial.

Published in:

Diabetes, Obesity & Metabolism, 2021, v. 23, n. 6, p. 1262, doi. 10.1111/dom.14334

By:

Whicher, Clare A.;
Price, Hermione C.;
Phiri, Peter;
Rathod, Shanaya;
Barnard‐Kelly, Katharine;
Ngianga, Kandala;
Thorne, Kerensa;
Asher, Carolyn;
Peveler, Robert C.;
McCarthy, Joanne;
Holt, Richard I. G.

Publication type:

Article

A randomized, placebo‐controlled study to evaluate the efficacy and safety of adding omarigliptin to insulin therapy in Japanese patients with type 2 diabetes and inadequate glycaemic control.

Published in:

Diabetes, Obesity & Metabolism, 2021, v. 23, n. 6, p. 1242, doi. 10.1111/dom.14331

By:

Kadowaki, Takashi;
Seino, Yutaka;
Kaku, Kohei;
Okamoto, Taro;
Kameya, Miho;
Sato, Asako;
Hirano, Tomona;
Oshima, Nobuyuki;
Gantz, Ira;
O'Neill, Edward A.;
Engel, Samuel S.

Publication type:

Article

Weight‐loss response to naltrexone/bupropion is modulated by the Taq1A genetic variant near DRD2 (rs1800497): A pilot study.

Published in:

Diabetes, Obesity & Metabolism, 2021, v. 23, n. 3, p. 850, doi. 10.1111/dom.14267

By:

Mullally, Jamie A.;
Chung, Wendy K.;
LeDuc, Charles A.;
Reid, Tirissa J.;
Febres, Gerardo;
Holleran, Steven;
Ramakrishnan, Rajasekhar;
Korner, Judith

Publication type:

Article

Patients' preferences for once‐daily oral versus once‐weekly injectable diabetes medications: The REVISE study.

Published in:

Diabetes, Obesity & Metabolism, 2021, v. 23, n. 2, p. 508, doi. 10.1111/dom.14244

By:

Boye, Kristina;
Ross, Melissa;
Mody, Reema;
Konig, Manige;
Gelhorn, Heather

Publication type:

Article

Antidiabetic medication use in commercially insured children and adolescents in the United States from 2004 to 2019.

Published in:

Diabetes, Obesity & Metabolism, 2021, v. 23, n. 2, p. 444, doi. 10.1111/dom.14237

By:

Sun, Jenny W.;
Hernández‐Díaz, Sonia;
Bourgeois, Florence T.;
Haneuse, Sebastien;
Brill, Gregory;
Bateman, Brian T.;
Huybrechts, Krista F.

Publication type:

Article